SAN DIEGO, Aug. 15, 2005 (PRIMEZONE) -- SpectraScience, Inc. (Pink Sheets:SCIE) announced today that it has filed a quarterly report covering the first six months of 2005 with the S.E.C. on Form 10-QSB. The report can be viewed at our web page www.spectrascience.com.
The Company develops and markets its proprietary WavStat(tm) Optical Biopsy System for use by physicians in diagnosing tissue to be normal, pre-cancerous, or cancerous. The WavStat(tm) System is currently approved for use in the colon. Other applications for detecting pre-cancers in the throat, sometimes called Barrett's esophagus, are under development.
This news release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from the results discussed in the forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, the Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB.and other documents.